Ann: Appendix 4E and Annual Report, page-8

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 8 Last

Share
Profile

Follow
lilgem

196 Posts.

29

30/08/22

10:20

Post #: 63401218
Share

Originally posted by showie: ↑

Listed Page number 14:

"Options and Rights Granted as Remuneration
On 19 June 2019, the Company announced 975,000 Employee Incentive Options under the Company’s employee
share and option plan, to be issued to Dr Keating, subject to Shareholder Approval. The options are exercisable
at $0.21 and expire five years from the date of issue. The options vest on the satisfaction of the following specific
performance milestones:
(i) CE Mark approval – 325,000 Options
(ii) FDA clearance – 325,000 Options
(iii) Commercial release of hardware product – 325,000 Options

Dr Keating is required to be employed by the Company in order to exercise the Incentive Options.
As at the date of this report, 975,000 Options have vested as the performance milestones of CE Mark approval,
FDA clearance and commercial release of hardware product have been achieved."

Listed Page number 14:

"For the year ended 30 June 2021, the Company issued a total of 6,250,000 Shares (equivalent to $500,000) to
Avanti in consideration for performance milestones achieved for the development of the handheld and wearable
devices, pursuant to the terms of the Device Development Agreement. The amounts were recognised as research
and development costs in the statement of profit or loss and other comprehensive income. The completion of the
CE Mark approval for the handheld device is still outstanding as of 30 June 2022."

I recall the device being CE marked already??

Also the 6250000 shares we offered to Tony's mate at the time (instead of cash) are now worth ~3x.. I'm glad Tony got his fill of options for a product that was never used. Are we aware if these specific options for TK were exercised already at $0.21?

Expand

Are we aware of anything, really? These reports are never as comprehensive as I feel they need to be. And was the FDA clearance that the 325K options for tk were vested on for any of our products? (was this specified?) Who knows with this mob...I won't be wasting my time reading any of the reports from today, just reading excerpts posted here is enough for me. In my opinion, these reports will be as 'informative' and 'balanced' as the ier (lol), so I really can't be bothered. Sticking to voting no until Pfizer go! imo and all the best to all of us

RAP Price at posting: 19.0¢ Sentiment: Hold Disclosure: Held
15 Upvote

0 Great analysis

Reply

Top Stories

BIT

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

RMX

Red Mountain Mining: record gold prices, two projects, two greenstone belts

CBA breaks trading record on strong day for Aussie financials

SBW

Shekel Brainweigh investor presentation webinar – the future of retail automation

There are more pages in this discussion • 53 more messages in this thread...

First 8 Last

Add RAP (ASX) to my watchlist

Ann: Appendix 4E and Annual Report, page-8

Top Stories

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

Red Mountain Mining: record gold prices, two projects, two greenstone belts

CBA breaks trading record on strong day for Aussie financials

Shekel Brainweigh investor presentation webinar – the future of retail automation

Featured News